News

David R. Chow, MD, provides an overview of new technological advancements for the vitreoretinal surgeon.

Pharmacotherapy research for diabetic macular edema is looking at targets other than VEGF inhibition to develop treatments that can be used as standalone intervention or may be complementary to current options.

The same photoactivation process used in collagen cross-linking for keratoconus can kill bacteria without the need for the oxygen responsible for the biomechanical effects, potentially pointing toward better treatments for keratitis, according to Olivier Richoz, MD, PhD.

Find out how to get your new staff members started on the right foot from Day One.

The IRIS Registry can improve patient outcomes by giving physicians access to information that could identify potential areas of quality improvement based on their patient population.

Ophthalmology Times is pleased to announce Amelia Fong, MD, of Georgetown University School of Medicine, Washington, DC, as the second-place winner of the publication’s 2015 Resident Writer’s Award Program, sponsored by Allergan. Dr. Fong’s entry is featured here.

Swept-source microscope-integrated ocular coherence tomography is an investigational real-time imaging technique for monitoring and guiding anterior segment procedures.

Acrylic expanders may be an option for the management of patients with congenital anophthalmos and microphthalmos.

Refractive laser platforms provide outstanding results, have reliable technology with excellent predictability and outcomes, and provide a broad range of applications. Better diagnostic imaging is possible with optical coherence tomography and Scheimpflug technology, and the advances of femtosecond lasers are moving into cataract surgery, said Michael Mrochen, PhD.

Were he alive today, he would likely feel heartened by how his work has been carried on by Gerd U. Auffarth, MD, FEBO, who is now director of The David J Apple International Laboratory for Ocular Pathology at the University of Heidelberg, Germany.

Topical regenerating agent eye drops speed up the corneal healing and reduce ocular discomfort after the epi-off crosslinking but more research is needed.

Things that strike terror in the hearts of many Americans-spiders, earthquakes, Ebola virus disease, and politicians with plans to “fix” healthcare-don't faze me much. But, for as long as I can remember, I have had this visceral negative reaction to snakes.

Developments in the field of corneal biomechanics will enable refractive surgeons to perform more precise surgery in the future.

With myopia on the rise, greater understanding of genetic and environmental factors is needed to refine interventions that may curtail disease progression.

Proprietary technology enhances corneal smoothness that resulted in a shorter recovery time of the visual acuity, higher levels of postoperative visual quality, and shorter time to re-epithelialization.

In a prospective study including 20 presbyopic emmetropes, treatment with a proprietary topical ophthalmic formulation (PresbV Tears) demonstrated benefit for improving near, intermediate, and far uncorrected visual acuity.

Topography-guided LASIK is a new option for treatment of myopia with or without astigmatism.

An IOL “super formula” may broaden the conceptual understanding of IOL calculations, improve clinical outcomes for patients, and stimulate further progress in IOL formula research.

Three-year follow-up from the phase I/IIa trial of rAAV.sFlt-1 subretinal injection is encouraging for gene therapy for exudative age-related macular degeneration.

The unexpected discovery of viable Ebola virus in the eye of a patient who had recovered from the systemic disease has strengthened efforts to learn more about ophthalmic and systemic complications of Ebola survivors and has translated to management and follow-up strategies in West Africa.

Pay attention to what staff members are thinking. Failure to do so may mean others will inadvertently hear about the issue at hand.

Eyes with hypotony after trabeculectomy might fare better than those without hypotony, a new study shows.

When visual field defects progress despite good IOP control, clinicians should look for other factors, according to Malik Y. Kahook, MD.

Companies that want to sell glaucoma products must start by building their own scientific expertise, said David E.I. Pyott, CBE, who was Allergan’s chief executive officer (CEO) and chairman of its board of directors from 1998 to 2015.

Companies specializing in glaucoma products can make billions of dollars, but only if they can find a path through a minefield of scientific, regulatory, and marketing hazards, according to Richard A. Lewis, MD.

The study of biomarkers for glaucoma is pointing to promising avenues for new treatments, according to Vivek J. Srinivasan, PhD.

Using valved cannulas during phacovitrectomy is highly recommended when an unexpected site hemorrhage becomes difficult to manage.